Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboringBRAFmutations in the Lung Cancer Mutation Consortium-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboringBRAFmutations in the Lung Cancer Mutation Consortium

Published:2014-10-01 Issue:3 Volume:121 Page:448-456
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Villaruz Liza C.¹,Socinski Mark A.¹,Abberbock Shira¹,Berry Lynne D.²,Johnson Bruce E.³,Kwiatkowski David J.⁴,Iafrate A. John⁵,Varella-Garcia Marileila⁶,Franklin Wilbur A.⁶,Camidge D. Ross⁶,Sequist Lecia V.⁵,Haura Eric B.⁷,Ladanyi Mark⁸,Kurland Brenda F.¹,Kugler Kelly⁶,Minna John D.⁹,Bunn Paul A.⁶,Kris Mark G.⁸

Affiliation:

1. University of Pittsburgh Cancer Institute; Pittsburgh Pennsylvania

2. Vanderbilt-Ingram Cancer Center; Nashville Tennessee

3. Dana-Farber Cancer Institute; Boston Massachusetts

4. Brigham and Women's Hospital; Boston Massachusetts

5. Massachusettes General Hospital; Boston Massachusetts

6. University of Colorado Cancer Center at Denver; Aurora Colorado

7. H. Lee Moffitt Cancer Center & Research Institute; Tampa Florida

8. Memorial Sloan-Kettering Cancer Center; New York New York

9. University of Texas Southwestern Medical Center; Dallas Texas

Funder

NIH

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference30 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

2. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

3. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib;Pao;Proc Natl Acad Sci U S A,2004

4. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N Engl J Med,2010

5. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients [abstract];Planchard;J Clin Oncol,2013

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study;Future Oncology;2024-09-03

2. A real world analysis of secondary BRAF variations after targeted therapy resistance in driver gene positive NSCLC;Scientific Reports;2024-09-01

3. Pathways and targeting avenues of BRAF in non-small cell lung cancer;Expert Opinion on Therapeutic Targets;2024-07-02

4. A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases;International Journal of Molecular Sciences;2024-06-26

5. The rapidly changing field of predictive biomarkers of non-small cell lung cancer;Pathology and Oncology Research;2024-06-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3